FluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer
Copenhagen, Denmark, 21 November 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the company has enrolled the first patient in the phase IIa trial with FG001 in head and neck cancer. The ongoing phase IIa trial is conducted in collaboration with Department of Otolaryngology, Head & Neck Surgery and Audiology at the University Hospital, Rigshospitalet in Denmark.The phase IIa trial is designed to obtain proof-of-concept in head and neck cancer for our uPAR platform technology used to guide surgical removal of cancer. The primary endpoint is sensitivity defined